Literature DB >> 14572469

Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction.

Jochen H Weishaupt1, Lothar Kussmaul, Philipp Grötsch, Armin Heckel, G Rohde, H Romig, Mathias Bähr, Frank Gillardon.   

Abstract

Previous studies suggested that pro-apoptotic stimuli may trigger a fatal reactivation of cell cycle elements in postmitotic neurons. Supporting this hypothesis, small molecule inhibitors of cyclin-dependent kinases (CDKs), which are known primarily as cell cycle regulators, are neuroprotective. However, available CDK inhibitors cannot discriminate between the different members of the CDK family and inhibit also CDK5, which is not involved in cell cycle control. Testing a new class of CDK inhibitors, we find that inhibitory activity against CDK5, but not cell cycle-relevant CDKs, confers neuroprotection. Moreover, we demonstrate that cleavage of the CDK5 activator protein p35 to p25 is associated with CDK5 overactivation after focal cerebral ischemia, but not in other models used in this study. We find that blocking CDK5 activity, but not caspase inhibition, protects mitochondrial integrity of lesioned neurons. Thus, in our models, CDK5, rather than cell cycle-relevant CDKs, activates neuronal cell death pathways upstream of mitochondrial dysfunction, and inhibition of CDK5 may promote functional long-term rescue of injured neurons. Moreover, we present the first CDK5-selective small molecule inhibitor, lacking unwanted cytostatic effects due to cross-inhibition of mitotic CDKs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572469     DOI: 10.1016/s1044-7431(03)00221-5

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  30 in total

1.  Sumoylation of p35 modulates p35/cyclin-dependent kinase (Cdk) 5 complex activity.

Authors:  Anja Büchner; Petranka Krumova; Sundar Ganesan; Mathias Bähr; Katrin Eckermann; Jochen H Weishaupt
Journal:  Neuromolecular Med       Date:  2014-11-13       Impact factor: 3.843

Review 2.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 3.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 4.  Cell cycle activation and spinal cord injury.

Authors:  Junfang Wu; Bogdan A Stoica; Alan I Faden
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 5.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

6.  Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.

Authors:  Wei Wang; Xiaoning Cao; Xiaolei Zhu; Yongliang Gu
Journal:  J Mol Model       Date:  2013-03-23       Impact factor: 1.810

7.  Overexpression of Cdk5 or non-phosphorylatable retinoblastoma protein protects septal neurons from oxygen-glucose deprivation.

Authors:  Kiran S Panickar; Doris Nonner; Michael G White; John N Barrett
Journal:  Neurochem Res       Date:  2008-03-20       Impact factor: 3.996

Review 8.  The Role of Cdk5 in Alzheimer's Disease.

Authors:  Shu-Lei Liu; Chong Wang; Teng Jiang; Lan Tan; Ang Xing; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-07-31       Impact factor: 5.590

Review 9.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

10.  Activation of cyclin-dependent kinase 5 is a consequence of cell death.

Authors:  Yixia Ye; Antonella Tinari; Walter Malorni; Richard A Lockshin; Zahra Zakeri
Journal:  J Biomed Biotechnol       Date:  2009-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.